173 related articles for article (PubMed ID: 38281232)
21. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
22. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.
Mantia C; Uhlmann EJ; Puligandla M; Weber GM; Neuberg D; Zwicker JI
Blood; 2017 Jun; 129(25):3379-3385. PubMed ID: 28468796
[TBL] [Abstract][Full Text] [Related]
23. Early vs. late enoxaparin for the prevention of venous thromboembolism in patients with ICH: A double blind placebo controlled multicenter study.
Qian C; Huhtakangas J; Juvela S; Bode MK; Tatlisumak T; Savolainen M; Numminen H; Ollikainen J; Luostarinen L; Kupila L; Tetri S
Clin Neurol Neurosurg; 2021 Mar; 202():106534. PubMed ID: 33578226
[TBL] [Abstract][Full Text] [Related]
24. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies.
Robinson R; Spectre G; Lishner M; Sharabi O; Robinson E; Hamburger Avnery O; Gafter-Gvili A; Raanani P; Leader A
J Thromb Thrombolysis; 2023 May; 55(4):729-736. PubMed ID: 36943661
[TBL] [Abstract][Full Text] [Related]
25. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
26. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis.
Zhou H; Chen TT; Ye LL; Ma JJ; Zhang JH
World J Surg Oncol; 2024 Feb; 22(1):69. PubMed ID: 38403630
[TBL] [Abstract][Full Text] [Related]
28. Enoxaparin Versus Direct Oral Anticoagulants for Venous Thromboembolism in Asians Undergoing Total Knee Arthroplasty: A Meta-Analysis and Systematic Review.
Chua CXK; Tan JHI; Bin Abd Razak HR
J Arthroplasty; 2022 Mar; 37(3):593-600.e1. PubMed ID: 34843908
[TBL] [Abstract][Full Text] [Related]
29. Low molecular weight heparin administration in cancer patients with hypercoagulability-related complications and carrying brain metastases: a case series study.
Vitale FV; Rotondo S; Sessa E; Parisi A; Giaimo V; D'Angelo A; Antonelli G; Romeo P; Ferraù F
J Oncol Pharm Pract; 2012 Mar; 18(1):10-6. PubMed ID: 21228085
[TBL] [Abstract][Full Text] [Related]
30. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study.
Klamroth R; Sinn M; Pollich C; Bischoff S; Lohneis A; Orlovic AM; Wisłocka L; Habbel P; de Wit M; Späth-Schwalbe E; Scholz CW; Riess H
Oncol Res Treat; 2022; 45(4):178-185. PubMed ID: 34963120
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Direct Oral Anticoagulant Therapy in Patients With Cancer.
Fovel LM; Seabury RW; Miller CD; Darko W; Probst LA; Horvath L
J Pharm Pract; 2021 Oct; 34(5):710-714. PubMed ID: 31888399
[TBL] [Abstract][Full Text] [Related]
33. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
[TBL] [Abstract][Full Text] [Related]
34. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
35. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
[TBL] [Abstract][Full Text] [Related]
36. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
Patel A; Williams H; Baer MR; Zimrin AB; Law JY
Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496
[TBL] [Abstract][Full Text] [Related]
37. Direct Oral Anticoagulants Are a Potential Alternative to Low-Molecular-Weight Heparin for Thromboprophylaxis in Trauma Patients Sustaining Lower Extremity Fractures.
Nederpelt CJ; Breen KA; El Hechi MW; Krijnen P; Huisman MV; Schipper IB; Kaafarani HMA; Rosenthal MG
J Surg Res; 2021 Feb; 258():324-331. PubMed ID: 33187673
[TBL] [Abstract][Full Text] [Related]
38. Operative spinal trauma: Thromboprophylaxis with low molecular weight heparin or a direct oral anticoagulant.
Hamidi M; Zeeshan M; Kulvatunyou N; Mitra HS; Hanna K; Tang A; Northcutt A; O'Keeffe T; Joseph B
J Thromb Haemost; 2019 Jun; 17(6):925-933. PubMed ID: 30924300
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis.
Ning H; Yang N; Ding Y; Chen H; Wang L; Han Y; Cheng G; Zou M
Med Clin (Barc); 2023 Mar; 160(6):245-252. PubMed ID: 36031454
[TBL] [Abstract][Full Text] [Related]
40. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
